These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33032051)

  • 1. Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder.
    Cai LJ; Zhang Q; Zhang Y; Chen HX; Shi ZY; Du Q; Zhou HY
    Mult Scler Relat Disord; 2020 Nov; 46():102515. PubMed ID: 33032051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very late onset neuromyelitis optica spectrum disorders.
    Nakahara K; Nakane S; Nagaishi A; Narita T; Matsuo H; Ando Y
    Eur J Neurol; 2021 Aug; 28(8):2574-2581. PubMed ID: 33960076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
    Hu Y; Sun Q; Yi F; Yao L; Tian Y; Tang H; Luo M; Xie N; Wang Z; Liao X; Zhou L; Xu H; Zhou Y
    Front Immunol; 2022; 13():1056944. PubMed ID: 36569880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Ariel B; Castillo MC; Cristiano E; Diégues Serva GB; Dos Santos AC; Finkelsteyn AM; López PA; Patrucco L; Molina O; Pettinicchi JP; Toneguzzo V; Caride A; Rojas JI
    J Neurol; 2020 May; 267(5):1260-1268. PubMed ID: 31932911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus.
    Sepulveda M; Delgado-García G; Blanco Y; Sola-Valls N; Martinez-Lapiscina EH; Armangué T; Montejo C; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Escudero D; Ruiz-García R; Llufriu S; Dalmau J; Graus F; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31471461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
    Drulovic J; Martinovic V; Basuroski ID; Mesaros S; Mader S; Weinshenker B; Pekmezovic T
    Mult Scler Relat Disord; 2019 Nov; 36():101413. PubMed ID: 31586803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders.
    Valdivia-Tangarife ER; Gamez-Nava JI; Cortés-Enríquez F; Mireles-Ramírez MA; Gonzalez-López L; Saldaña-Cruz AM; Macías-Islas MA
    Mult Scler Relat Disord; 2022 Dec; 68():104114. PubMed ID: 36037753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.
    Mealy MA; Mossburg SE; Kim SH; Messina S; Borisow N; Lopez-Gonzalez R; Ospina JP; Scheel M; Yeshokumar AK; Awad A; Leite MI; Arango JJ; Paul F; Palace J; Kim HJ; Levy M
    Mult Scler Relat Disord; 2019 Feb; 28():64-68. PubMed ID: 30554040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features.
    Yu J; Yan S; Niu P; Teng J
    Front Neurol; 2022; 13():859276. PubMed ID: 35493805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
    Luo W; Wang X; Kong L; Chen H; Shi Z; Zhou H
    J Neuroimmunol; 2024 Mar; 388():578263. PubMed ID: 38309224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset neuromyelitis optica spectrum disorder: A case series from Iran.
    Ghadiri F; Eskandarieh S; Sahraian MA; Azimi A; Moghadasi AN
    Rev Neurol (Paris); 2022 Mar; 178(3):249-252. PubMed ID: 34776261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders.
    Zhang LJ; Yang LN; Li T; Wang J; Qi Y; Zhang DQ; Yang CS; Yang L
    Int J Neurosci; 2017 Apr; 127(4):334-338. PubMed ID: 27788616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Early- and Late-Onset NMOSD-Related Optic Neuritis in Thai Patients: Clinical Characteristics and Long-Term Visual Outcomes.
    Thongmee W; Narongkhananukul C; Padungkiatsagul T; Jindahra P; Vanikieti K
    Clin Ophthalmol; 2021; 15():419-429. PubMed ID: 33574650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder.
    Nakamura Y; Liu Z; Fukumoto S; Shinoda K; Sakoda A; Matsushita T; Hayashida S; Isobe N; Watanabe M; Hiwatashi A; Yamasaki R; Kira JI
    Eur J Neurol; 2020 Jan; 27(1):92-99. PubMed ID: 31304648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.